Halozyme Therapeutics, a leading biopharmaceutical company, is proud to announce the appointment of Dr. Mahesh Krishnan to its Board of Directors. Dr. Krishnan brings a wealth of experience in healthcare, biotechnology, and health services, making him a valuable addition to the board.
Dr. Krishnan currently serves as Group Vice President of Growth at DaVita, Inc., a renowned provider of kidney care services in the U.S. During his tenure, he played a pivotal role in overseeing strategic partnerships and research and development within the organization. Additionally, he holds responsibilities for medical policy aspects in Washington, D.C.
With over two decades of experience, Dr. Krishnan has held significant positions in the healthcare industry. He previously served as DaVita’s Group Vice President of Research and Development and was their first international Chief Medical Officer. Prior to that, he played various roles at Amgen Inc., a leading biotechnology company.
Halozyme is confident that Dr. Krishnan’s expertise and insights will be instrumental as the company expands its leadership in innovative drug delivery technologies. Halozyme is widely recognized for its ENHANZE® drug delivery technology, which uses the proprietary enzyme rHuPH20 to facilitate the subcutaneous delivery of injected drugs and fluids. This technology aims to reduce treatment burden for patients.
Halozyme’s ENHANZE® technology has already touched the lives of over 800,000 patients across more than 100 global markets. The company has licensed this technology to several pharmaceutical and biotechnology companies, including Roche, Takeda, Pfizer, and Janssen.
In addition to their drug delivery technology, Halozyme also develops and commercializes drug-device combination products using advanced auto-injector technologies. These products aim to enhance convenience, reliability, and patient comfort and adherence.
Headquartered in San Diego, with offices in Ewing, NJ, and Minnetonka, MN, Halozyme is committed to improving patient experiences and outcomes for both emerging and established therapies.
For more information about Halozyme and its innovative solutions, please visit www.halozyme.com. Stay connected with Halozyme on LinkedIn and Twitter for the latest updates.
Disclaimer: This article contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed in the forward-looking statements. Readers are advised to refer to the Company’s most recent Annual Report on Form 10-K for a detailed discussion of factors that may impact future results and developments.
Halozyme Therapeutics, a leading biopharmaceutical company, has recently announced the appointment of Dr. Mahesh Krishnan to its Board of Directors. Dr. Krishnan brings extensive experience in healthcare, biotechnology, and health services, which makes him a valuable addition to the board. Currently serving as Group Vice President of Growth at DaVita, Inc., a renowned provider of kidney care services in the U.S., Dr. Krishnan has played a pivotal role in overseeing strategic partnerships and research and development within the organization. He also holds responsibilities for medical policy aspects in Washington, D.C.
Dr. Krishnan’s impressive background includes previous roles such as DaVita’s Group Vice President of Research and Development and its first international Chief Medical Officer. He has also held various positions at Amgen Inc., a leading biotechnology company. With over two decades of experience in the healthcare industry, Dr. Krishnan’s expertise and insights are expected to be instrumental in Halozyme’s expansion as a leader in innovative drug delivery technologies.
One of the key technologies developed by Halozyme is their ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate the subcutaneous delivery of injected drugs and fluids. This technology aims to reduce the treatment burden for patients. Halozyme’s ENHANZE® technology has already benefited over 800,000 patients in more than 100 global markets. The company has licensed this technology to several pharmaceutical and biotechnology companies, including Roche, Takeda, Pfizer, and Janssen.
In addition to their drug delivery technology, Halozyme also focuses on developing and commercializing drug-device combination products using advanced auto-injector technologies. These products aim to enhance convenience, reliability, patient comfort, and adherence.
Halozyme’s headquarters is in San Diego, with offices in Ewing, NJ, and Minnetonka, MN. The company is committed to improving patient experiences and outcomes for both emerging and established therapies.
While Halozyme’s innovative solutions have shown promise, it’s important to note that this article contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed in the forward-looking statements. Readers are advised to refer to the Company’s most recent Annual Report on Form 10-K for a detailed discussion of factors that may impact future results and developments.
For more information about Halozyme and its innovative solutions, please visit their official website: www.halozyme.com. Stay connected with Halozyme on LinkedIn and Twitter for the latest updates.
Please note that by clicking on the links above, you will be redirected to external websites.